Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' DEFICIT (Details 3)

v3.6.0.2
STOCKHOLDERS' DEFICIT (Details 3) - Warrants [Member] - $ / shares
 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding, beginning 3,912 4,078
Granted 604,000 [1] 1,000
Exercised
Expired (752) (1,166)
Forfeited (600,000)  
Outstanding, ending 7,160 3,912
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]    
Outstanding, beginning $ 106.00 $ 614.00
Granted 10.00 50.00
Exercised
Expired 200.00 1,828.00
Forfeited 10.00  
Outstanding, ending $ 50.41 $ 106.00
[1] Pursuant to the Second Amended Note & Warrant Agreement, dated December 23, 2015, the Company issued an aggregate 600,000 warrants with same terms as the warrants mentioned in (1) above. On September 19, 2016, the Company entered into the Second Omnibus Amendment, with a majority of over 80% of the noteholders, thereby amending: (i) the Notes, (ii) the Second Amended Note and Warrant Agreement, as amended and (iii) the Warrants. Subsequently, the Company exercised the Mandatory Conversion on September 19, 2016, and, on September 21, 2016, (i) converted the entire outstanding principal balance of $6,000,000, plus accrued interest of $317,000 on all of the Notes into 1,263,406 shares of the Company's Common Stock at a conversion price of $5.00 per share and (ii) cancelled all 600,000 issued and outstanding warrants associated with the Notes. (refer to Note 3. Convertible Debt and Equity Financing).